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Background
Ovarian cancer still remains the deadliest cancer of the
female reproductive tract. Unfortunately, most cases are
diagnosed in the late stages of the disease. The most
useful tumor marker in the detection of ovarian cancer
is cancer antigen (CA) 125. The greatest problem of CA
125 determination is its lack of specificity. Aim To eval-
uate the clinicopathological features of ovarian tumors
and their correlation with the serum markers like
CA125 in detecting ovarian tumors.
Methods
A retrospective analysis of ovarian tumor patients, treated
at Gynecology and Obstetric department in Saqr hospital
between 2011-2013, was performed. All the socioepide-
miological and clinicopathological features were retrieved
from the patient’s files.
Results
Number of Cases: 45 All the 45 patients included in the
study had benign ovarian masses. Age Range: 15-64 yrs,
type of ovarian tumor percentage (%), Dermoid cyst
(teratoma), 35.5 serous tumors, 33.1 Chocolate cyst,
13 Paraovarian cyst, 13 Follicular cysts, 2.2 Malignancy,
2.2 Approximately 35.5% of the cases were mature cystic
teratoma, followed by serous cystadenoma (33.1%). The
right ovary was involved in 56.2%, the left ovary in
31.2% and bilateral ovaries were involved in 12.5%. The
serum levels of CA125: The mean serum level was
90.5±99.5 (range 7.0-294).
Conclusions
The diagnostic value of serum CA125 in distinguishing
a benign from a malignant ovarian mass is important,
but the main limit of serum CA125 is that it may be
high in benign diseases, especially in the reproductive age.
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